A new nuclear medicine procedure pioneered in Pretoria
The South African Nuclear Energy Corporation’s (Necsa’s) subsidiary company NTP Radioisotopes has, in conjunction with the Steve Biko Academic Hospital/University of Pretoria and Germany’s ITG Isotopes Technologies Garching, undertaken a new anti-cancer procedure in a human being for the first time. The procedure was carried out by a team led by the hospital’s head of nuclear medicine, Professor Mike Sathekge, assisted by ITG’s Dr Sebastian Marx and Dr Marian Meckel and NTP’s Dr Otto Knoesen.
The new procedure is an example of the theranostic approach, which combines radiopharmaceutical diagnosis and treatment, and is aimed at secondary cancers in the bone (or, more technically, “osseous metastases”), mainly derived from primary cancers in the breast or prostate. These bone cancers greatly reduce the quality of life for the patient, causing acute pain and even fracturing bones.
The diagnosis of the patient was conducted using positron emission tomography/computed tomography (better known as PET/CT) employing the positron-emitting radiopharmaceutical Gallium-68 Zoledronate. (A positron is the anti-matter equivalent of an electron; zoledronate is zometa zoldedronic acid, a compound used to slow down the destruction of bone by secondary bone cancers.) The treatment is then carried out using Lutetium-177 Zoledronate therapy, developed by ITG.
More precisely, the therapy employs Lutetium-177 (III)-labelled DOTA-Zoledronate. (Dota is also an acid.) The Lutetium-177 is no carrier added (nca: pure) and emits low energy Beta-particles, which are frequently employed in targetted radionuclide therapy. Currently, Lutetium-177 nca is imported into South Africa from ITG in Germany, but local production will soon start at NTP’s new production plant at the Necsa complex at Pelindaba, west of Pretoria.
The new procedure permits the development of individual patient-specific therapeutic doses – an example of personalised medicine. In a statement, NTP affirmed that “radiopharmaceuticals will continue to play a key and growing role in the assessment and therapy of numerous diseases”.
Comments
The
content
you are trying to access is only available to subscribers.
If you are already a subscriber, you can Login Here.
If you are not a subscriber, you can subscribe now, by selecting one of the below options.
For more information or assistance, please contact us at subscriptions@creamermedia.co.za.
Option 1 (equivalent of R125 a month):
Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format
Option 2 (equivalent of R375 a month):
All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors
including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.
Already a subscriber?
Forgotten your password?
Receive weekly copy of Creamer Media's Engineering News & Mining Weekly magazine (print copy for those in South Africa and e-magazine for those outside of South Africa)
➕
Recieve daily email newsletters
➕
Access to full search results
➕
Access archive of magazine back copies
➕
Access to Projects in Progress
➕
Access to ONE Research Report of your choice in PDF format
RESEARCH CHANNEL AFRICA
R4500 (equivalent of R375 a month)
SUBSCRIBEAll benefits from Option 1
➕
Access to Creamer Media's Research Channel Africa for ALL Research Reports on various industrial and mining sectors, in PDF format, including on:
Electricity
➕
Water
➕
Energy Transition
➕
Hydrogen
➕
Roads, Rail and Ports
➕
Coal
➕
Gold
➕
Platinum
➕
Battery Metals
➕
etc.
Receive all benefits from Option 1 or Option 2 delivered to numerous people at your company
➕
Multiple User names and Passwords for simultaneous log-ins
➕
Intranet integration access to all in your organisation